Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Blood Test Differentiates Severe COVID-19 from Preeclampsia in Pregnant Women

By LabMedica International staff writers
Posted on 27 Apr 2022

Preeclampsia is an inflammatory condition that appears during pregnancy and whose cause is still unknown. More...

This condition is characterized by high blood pressure combined with organ dysfunctions, such as renal and liver failure. Should preeclampsia not be early diagnosed, it can lead to serious complications for the mother and the baby. Induced delivery and placenta removal are currently the only solution for this condition. Pregnant women who may have preeclampsia may also be tested positive on COVID-19. In those cases, there may be doubts whether they suffer from preeclampsia and asymptomatic COVID-19 or only have COVID-19 with no preeclampsia, as both pathologies present similar clinical signs. Now, a new study has identified indicators which enable differentiating between both pathologies, thus paving the way for a more accurate diagnosis for both diseases and a better risk assessment.

In the new study, researchers at the Josep Carreras Leukemia Research Institute (IJC, Barcelona, Spain) questioned the extent to which preeclampsia and COVID-19 share biological characteristics. They assessed indicators of endothelial dysfunction, blood clotting, angiogenesis and immune function from blood of pregnant women with preeclampsia or COVID-19 and compared them with of healthy pregnant women’s. The research team were successfully able to differentiate preeclampsia from severe COVID-19, thanks to the strong and reproducible differences in the panel of indicators, being angiogenesis (sFlt-1, Ang2 and P1GF), blood clotting (antigen vWF) and endothelial damage (VCAM-1 and sTNFRI) the most patent.

The study also shows that there are shared elements between both pathologies such as the activation of the complement system, an important part of the immune system, even if the alterations caused by COVID-19 are less significant than the ones caused by preeclampsia. These outcomes are a further step in preeclampsia characterization, a little-known pregnancy-related disease but main responsible for maternal and perinatal mortality in the world and premature births. These results are also medically relevant, as they offer diagnostic tools which allow distinguishing preeclampsia from COVID-19 and helping in their clinical management and treatment. The results of the study are considered as the most important review in gynecology.

Related Links:
IJC 


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Automated Urinalysis Solution
UN-9000
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.